These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of a new antirheumatic drug (CGS10787B) on antibody formation and delayed-type hypersensitivity in BALB/c mice.
    Author: Akita S, Abe C, Hirose S.
    Journal: Int J Tissue React; 1988; 10(4):199-205. PubMed ID: 3266939.
    Abstract:
    The effect of CGS10787B on antibody formation and cell-mediated (delayed-type) hypersensitivity in BALB/c mice was examined by using the haemolytic plaque-forming cell assay and the delayed-type footpad reaction with the assay of T-cell subsets. CGS10787B at doses of 5, 25 and 100 mg/kg p.o. enhanced spleen haemolytic plaque-formation on day 4, and spleen rosette-formation on day 5 after immunization. In the assay of T-cell subsets, CGS10787B at the dose of 100 mg/kg reduced the Lyt-23 positive cell subset. In type III hypersensitivity, CGS10787B at doses of 5, 25 and 100 mg/kg p.o. for 6 days reduced dose-relatedly the footpad swelling of the immunized mouse. In type IV hypersensitivity, CGS10787B at doses of 5, 25 and 100 mg/kg p.o. for 6 days diminished dose-dependently the footpad swelling augmented by cyclophosphamide pretreatment. In the assay of T-cell subsets, CGS10787B at doses of 25 and 100 mg/kg increased the Thy-1 positive cell subset. These findings suggest that CGS10787B has an influence on the immune systems, acting on the function of T lymphocytes as well as on the inflammatory process in immunized animals.
    [Abstract] [Full Text] [Related] [New Search]